RapidFire BLAZE-Mode Is Boosting ESI-MS Toward High-Throughput-Screening.


Journal

SLAS technology
ISSN: 2472-6311
Titre abrégé: SLAS Technol
Pays: United States
ID NLM: 101697564

Informations de publication

Date de publication:
08 2019
Historique:
pubmed: 31 1 2019
medline: 10 4 2020
entrez: 31 1 2019
Statut: ppublish

Résumé

Label-free in vitro potency assays are an emerging field in drug discovery to enable more physiological conditions, to improve the readout quality, and to save time. For this approach mass spectrometry (MS) is a powerful technology to directly follow physiological processes. The speed of this methodology, however, was for a long time not compatible with chemiluminescence- or fluorescence-based assays. Recent advances in matrix-assisted laser desorption/ionization (MALDI) instrumentation paved the way for high-throughput MS analysis of label-free assays for large compound libraries, whereas electrospray ionization (ESI)-based mass spectrometers equipped with RapidFire autosamplers were limited to medium throughput. Here we present a technological advancement of the RapidFire device to enable cycle times of 2.5 s per sample. This newly developed BLAZE-mode substantially boosted the ESI-MS analysis speed, providing an alternative technology for label-free high-throughput screening.

Identifiants

pubmed: 30698995
doi: 10.1177/2472630318822449
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

386-393

Auteurs

Tom Bretschneider (T)

1 Boehringer Ingelheim Pharma GmbH & Co. KG, Drug Discovery Sciences, Biberach an der Riß, Germany.

Can Ozbal (C)

2 PureHoney Technologies, Billerica, MA, USA.

Markus Holstein (M)

1 Boehringer Ingelheim Pharma GmbH & Co. KG, Drug Discovery Sciences, Biberach an der Riß, Germany.

Martin Winter (M)

1 Boehringer Ingelheim Pharma GmbH & Co. KG, Drug Discovery Sciences, Biberach an der Riß, Germany.

Frank H Buettner (FH)

1 Boehringer Ingelheim Pharma GmbH & Co. KG, Drug Discovery Sciences, Biberach an der Riß, Germany.

Sven Thamm (S)

1 Boehringer Ingelheim Pharma GmbH & Co. KG, Drug Discovery Sciences, Biberach an der Riß, Germany.

Daniel Bischoff (D)

1 Boehringer Ingelheim Pharma GmbH & Co. KG, Drug Discovery Sciences, Biberach an der Riß, Germany.

Andreas H Luippold (AH)

1 Boehringer Ingelheim Pharma GmbH & Co. KG, Drug Discovery Sciences, Biberach an der Riß, Germany.

Articles similaires

Humans Chondrocytes Osteoarthritis Matrix Metalloproteinase 13 Drug Discovery
Glycoside Hydrolase Inhibitors Quantitative Structure-Activity Relationship Molecular Docking Simulation alpha-Glucosidases Molecular Dynamics Simulation
Neural Networks, Computer Drug Discovery Humans Drug Repositioning
Drug Design Models, Chemical Endopeptidase Clp Drug Discovery Humans

Classifications MeSH